MTOR and breast carcinoma: In 2012, the U.S. FDA approved everolimus (RAD001) as the first PI3K/AKT/mTOR pathway inhibitor for the treatment of advanced ER+ breast cancer in combination with the steroidal AI exemestane following progression on a non-steroidal AI.